OncoCyte (OCX)

• Market cap: $75.8M
• 1 day: -1.85%
• 5 days: -8.93%
• 1 month: -4.33%
• 3 months: -31.52%
• 6 months: 14.22%
• Year to date: 13.73%
• 1 year: -2.93%
• 5 years: -94.43%
• 10 years: -98.53%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.

Employees: 49

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

146% more capital invested

Capital invested by funds: $20M [Q4 2024] → $49.2M (+$29.2M) [Q1 2025]

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

15% more funds holding

Funds holding: 26 [Q4 2024] → 30 (+4) [Q1 2025]

6.29% more ownership

Funds ownership: 49.97% [Q4 2024] → 56.27% (+6.29%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 51% upside
• Avg. target: $5.42 104% upside
• High target: $8 202% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Lake Street Thomas Flaten	202% upside $8	Buy Maintained	21 May 2025
Needham Mike Matson	60% upside $4.25	Buy Reiterated	13 May 2025
Stephens & Co. Mason Carrico	51% upside $4	Equal-Weight Reiterated	26 Mar 2025